Sage Journals: Discover world-class research

Retricted access

Research article

First published 2012-11

Are Pharmaceutical Market Withdrawals Preventable? A Preliminary Analysis

Jaya Sai V. Daggumalli, Irwin G. Martin

Therapeutic Innovation & Regulatory Science

Retricted access

Other

First published 2001-1

Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999 *

Man Fung, Anna Thornton, Kathy Mybeck [...]

Therapeutic Innovation & Regulatory Science

Open access

Research article

First published 2022

Clinical outcomes following switching antipsychotic treatment due to market withdrawal: a retrospective naturalistic cohort study of pipotiazine palmitate injection (Piportil Depot) discontinuation,subsequent acute care use and effectiveness of medication to which patients switched

Rollo J.G. Sheldon, Marco Pereira, George Aldersley [...]

Therapeutic Advances in Psychopharmacology

Retricted access

Research article

First published 2021-11

Companies’ statements about drugs withdrawn from the Canadian market: A descriptive analysis

Joel Lexchin

International Journal of Risk & Safety in Medicine

Retricted access

Research article

First published 2026

Smoking Habits in Financial Markets: Nicotine,Stock Returns and Rationality

Evangelos Vasileiou

Journal of Interdisciplinary Economics

Retricted access

Other

First published 2001-4

Withdrawal of Marketed Drugs and ADR Reporting

Joyce Generali

Hospital Pharmacy

Retricted access

Letter

First published 1998-7

Mibefradil Withdrawn from the Market

Sarah J Billups, Barry L Carter

Annals of Pharmacotherapy

Retricted access

Editorial

First published 2007-7

The Pharmacist's Role in the Changing World of Drug Recalls and Market Withdrawals

Joyce Generali

Hospital Pharmacy

Retricted access

Research article

First published 2024

Withdrawal of Open Offer: Impact  on Merger and Acquisition  Transactions in India

Supriya Dash, Bindu S Ronald, Sachchidanand Prasad [...]

Business Perspectives and Research

Retricted access

Research article

First published 2018-9

Analysis of the Risks and Benefits of New Chemical Entities Approved by the US Food and Drug Administration (FDA) and Subsequently Withdrawn From the US Market

Peter A. Patriarca, R. Michael Van Auken, Scott A. Kebschull

Therapeutic Innovation & Regulatory Science

Search results